Impact of CHA2DS2-VASc Score and Anticoagulant Use on Stroke Treatment Outcomes
Author Information
Author(s): Y. Imaoka, R. Nice, S. Ogata, H. Imamura, Y. Kaku, K. Arimura, S. Watanabe, E. Kiyoshige, K. Nishimura, S. Kobashi, M. Ihara, K. Kamiyama, M. Morimoto, T. Ohta, H. Endo, Y. Matsumaru, N. Sakai, T. Kitazono, S. Fujimoto, K. Ogasawara, K. Iihara
Primary Institution: National Cerebral and Cardiovascular Center, Osaka, Japan
Hypothesis
The study evaluates the effect of CHA2DS2-VASc score and prior use of oral anticoagulants on endovascular treatment outcomes in patients with acute ischemic stroke and atrial fibrillation.
Conclusion
Prior use of direct oral anticoagulants improves successful and complete reperfusion rates in high-risk patients, while warfarin use increases the risk of complications.
Supporting Evidence
- Higher CHA2DS2-VASc scores were linked to worse outcomes after treatment.
- Prior DOAC use improved successful reperfusion rates in high-risk patients.
- Warfarin use was associated with increased risk of symptomatic intracerebral hemorrhage.
Takeaway
This study found that using certain blood thinners before a stroke can help patients recover better after treatment, but using another type can lead to more problems.
Methodology
The study analyzed data from 6984 patients with atrial fibrillation who received endovascular treatment across 353 centers in Japan, focusing on outcomes related to CHA2DS2-VASc scores and prior anticoagulant use.
Potential Biases
Potential selection bias from participating hospitals and confounding factors related to patient backgrounds.
Limitations
The study's findings may not be generalizable to other populations, and it was retrospective, which could introduce bias.
Participant Demographics
Median age was 80 years, with 48.5% female participants.
Statistical Information
P-Value
p=0.003
Confidence Interval
1.00–1.61
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website